AQB 565Alternative Names: AQB 565
Latest Information Update: 17 Feb 2017
At a glance
- Originator Aequus BioPharma
- Class Antigouts; Peptide hormones; Recombinant fusion proteins
- Mechanism of Action Corticotropin receptor agonists; Melanin stimulants; Melanocyte modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gout